Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Sangamo Therapeutics, Inc.
(https://sangamo.com) 📸 Data Snapshot: June 19, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Sangamo Therapeutics, Inc. | Pioneering Genetic Cures (https://sangamo.com)
Sangamo Therapeutics, Inc. | Pioneering Genetic Cures
Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene regulation.
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Sangamo Programs On Genomic Medicine | Sangamo Therapeutics, Inc. (https://sangamo.com/programs/)
Sangamo Programs On Genomic Medicine | Sangamo Therapeutics, Inc.
We are pursuing programs across the spectrum of genomic medicine, with gene and cell therapies in the clinic today and preclinical programs in genome engineering.
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Science Behind Genomic Medicines | Sangamo Therapeutics, Inc. (https://sangamo.com/science/)
Science Behind Genomic Medicines | Sangamo Therapeutics, Inc.
Sangamo’s technology platform enables us to make genomic medicines using ex vivo cell therapy, in vivo genome engineering, and gene therapy. Click to know more.
NAV_HEADER_REPEATED_FOOTER Our Commitment to Serve Patients | Sangamo Therapeutics, Inc. (https://sangamo.com/patients/)
Our Commitment to Serve Patients | Sangamo Therapeutics, Inc.
Our commitment to patients requires that we partner with them, their caregivers, families & community so all stakeholders understand the potential of genomic medicine.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE · THIN (https://sangamo.com) Sangamo Therapeutics, Inc. | Pioneering Genetic Cures
[H2] Pioneering the future of genomic medicine Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today’s medicine can only offer symptom management at best. Explore our pipeline
SUB-PAGE (https://sangamo.com/programs/) Sangamo Programs On Genomic Medicine | Sangamo Therapeutics, Inc.
[H4] Our Partners Sangamo and Alexion are collaborating for the development and commercialization of therapeutics using our zinc finger transcription factors (ZF-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene. Astellas and Sangamo have entered into a worldwide exclusive license agreement allowing Astellas to use Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, for up to five neurological disease targets. Sangamo has a global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases, focused on the tau gene, which is critically involved in Alzheimer’s disease and other tauopathies, as well as a second undisclosed neurology target. Lilly and Sangamo have entered into a worldwide exclusive license agreement allowing Lilly to use Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, for up to five potential disease targets of the central nervous system. [IMG: Image: Takeda Logo] Takeda and Sangamo are developing therapeutics for Huntington's disease utilizing our epigenetic regulation platform. Interested in collaborating with us? Contact Stephanie Seiler, Head of Business Development and Alliance Management Contact Stephanie
SUB-PAGE · THIN (https://sangamo.com/science/) Science Behind Genomic Medicines | Sangamo Therapeutics, Inc.
[H3] Zinc Finger Platform Sangamo’s proprietary zinc finger (ZF) platform uniquely confers a number of advantages and has broad therapeutic potential due to its versatility, specificity, clinical utility and compact nature. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on the therapeutic needs. Due to their compact size, ZF technologies are highly compatible with delivery vectors. Learn more about our zinc finger platform
SUB-PAGE · THIN (https://sangamo.com/patients/) Our Commitment to Serve Patients | Sangamo Therapeutics, Inc.
[H3] Our commitment to patients Our primary goal is creating new medicines for patients who need them. The first step toward that goal is understanding patient needs, perspectives and expectations. We engage patients and patient advocacy groups from the beginning of our development process to inform how we develop genomic medicines and design clinical trials that will best meet patient needs.
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 2 | 0 |
| /programs/ | 4 | 0 |
| /science/ | 2 | 0 |
| /patients/ | 2 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.sangamo.com/",
"url": "https://www.sangamo.com/",
"name": "Sangamo Therapeutics, Inc. | Pioneering Genetic Cures",
"isPartOf": {
"@id": "https://www.sangamo.com/#website"
},
"datePublished": "2021-05-19T16:13:07+00:00",
"dateModified": "2026-05-12T14:00:27+00:00",
"description": "Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene regulation.",
"breadcrumb": {
"@id": "https://www.sangamo.com/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://www.sangamo.com/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://www.sangamo.com/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home"
}
]
},
{
"@type": "WebSite",
"@id": "https://www.sangamo.com/#website",
"url": "https://www.sangamo.com/",
"name": "Sangamo",
"description": "",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://www.sangamo.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
}
]
}
/programs/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.sangamo.com/programs/",
"url": "https://www.sangamo.com/programs/",
"name": "Sangamo Programs On Genomic Medicine | Sangamo Therapeutics, Inc.",
"isPartOf": {
"@id": "https://www.sangamo.com/#website"
},
"datePublished": "2021-05-19T16:12:18+00:00",
"dateModified": "2026-04-23T16:52:59+00:00",
"description": "We are pursuing programs across the spectrum of genomic medicine, with gene and cell therapies in the clinic today and preclinical programs in genome engineering.",
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://www.sangamo.com/programs/"
]
}
]
},
{
"@type": "WebSite",
"@id": "https://www.sangamo.com/#website",
"url": "https://www.sangamo.com/",
"name": "Sangamo",
"description": "",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://www.sangamo.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
}
]
}
/science/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.sangamo.com/science/",
"url": "https://www.sangamo.com/science/",
"name": "Science Behind Genomic Medicines | Sangamo Therapeutics, Inc.",
"isPartOf": {
"@id": "https://www.sangamo.com/#website"
},
"datePublished": "2021-05-19T16:12:42+00:00",
"dateModified": "2025-11-15T01:28:43+00:00",
"description": "Sangamo’s technology platform enables us to make genomic medicines using ex vivo cell therapy, in vivo genome engineering, and gene therapy. Click to know more.",
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://www.sangamo.com/science/"
]
}
]
},
{
"@type": "WebSite",
"@id": "https://www.sangamo.com/#website",
"url": "https://www.sangamo.com/",
"name": "Sangamo",
"description": "",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://www.sangamo.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
}
]
}
/patients/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.sangamo.com/patients/",
"url": "https://www.sangamo.com/patients/",
"name": "Our Commitment to Serve Patients | Sangamo Therapeutics, Inc.",
"isPartOf": {
"@id": "https://www.sangamo.com/#website"
},
"primaryImageOfPage": {
"@id": "https://www.sangamo.com/patients/#primaryimage"
},
"image": {
"@id": "https://www.sangamo.com/patients/#primaryimage"
},
"thumbnailUrl": "https://www.sangamo.com/wp-content/uploads/2021/06/Sandy_Macrae-1.png",
"datePublished": "2021-05-19T16:11:57+00:00",
"dateModified": "2024-11-19T20:40:03+00:00",
"description": "Our commitment to patients requires that we partner with them, their caregivers, families & community so all stakeholders understand the potential of genomic medicine.",
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://www.sangamo.com/patients/"
]
}
]
},
{
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://www.sangamo.com/patients/#primaryimage",
"url": "https://www.sangamo.com/wp-content/uploads/2021/06/Sandy_Macrae-1.png",
"contentUrl": "https://www.sangamo.com/wp-content/uploads/2021/06/Sandy_Macrae-1.png",
"width": 350,
"height": 240,
"caption": "Sandy Macrae"
},
{
"@type": "WebSite",
"@id": "https://www.sangamo.com/#website",
"url": "https://www.sangamo.com/",
"name": "Sangamo",
"description": "",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://www.sangamo.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
}
]
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Sangamo Therapeutics, Inc. (sangamo.com)
Sangamo Therapeutics presents a high-substance technical front that effectively backs up its ‘groundbreaking’ claims with specific clinical and preclinical identifiers. The BS score is primarily elevated by ‘trust theatre’ artifacts like unverified review counts and a lack of structured data for its leadership. For a biotech, the content is remarkably transparent, though the corporate marketing layer remains predictably thick.
1. Remove the review schema and rating widgets, as ‘review counts’ on clinical program pages undermine regulatory credibility. 2. Supplement technical H3 headings with direct outbound links to ClinicalTrials.gov (NCT numbers) and peer-reviewed journals. 3. Implement Organization and Person schema to provide a verifiable digital footprint for named executives and the company’s historical headquarters. 4. Update the H1 ‘tomorrow’s cures’ to include a specific therapeutic focus (e.g., ‘Advancing Zinc Finger Cures for Fabry and Neurology’) to further reduce fluff saturation.
The site content perfectly aligns with the Pharma & Biotech industry, specifically focusing on genomic medicine, gene therapy, and zinc finger technology. The presence of specific drug identifiers (ST-920, ST-503), clinical trial phases (Phase 1/2 STAAR study), and partnership details with major pharma (Genentech, Takeda, Lilly) confirms high industry relevance.
“The score of 30 reflects a 'Low BS' profile. The primary drivers of the score were Trust and Proof (11/20) due to the trust theatre flag and Identity/Authority (7/15) due to missing leadership schema. The scientific substance (Information Density) and cross-page consistency (Semantic Coherence) are exceptionally strong for this category, keeping the total score well below the moderate range.”
This training module utilizes a snapshot of public data from Sangamo Therapeutics, Inc., captured on June 19, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Sangamo Therapeutics, Inc.: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://sangamo.com to view the most current version of its content and learn from the source what this company is about and what it offers.